D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
78,700
-3,100 (-3.79%)
Apr 28, 2026, 3:30 PM KST
374.10%
Market Cap 3.45T
Revenue (ttm) 4.30B
Net Income (ttm) -23.55B
Shares Out 43.80M
EPS (ttm) -547.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 390,995
Average Volume 501,902
Open 79,900
Previous Close 81,800
Day's Range 78,200 - 80,300
52-Week Range 14,550 - 113,700
Beta n/a
RSI 50.97
Earnings Date Apr 3, 2026

About D&D Pharmatech

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

In 2025, D&D Pharmatech's revenue was 4.30 billion, a decrease of -62.42% compared to the previous year's 11.44 billion. Losses were -23.55 billion, -17.71% less than in 2024.

Financial Statements

News

There is no news available yet.